Navidea Biopharmaceuticals (NAVBQ)

Executive Summary

Navidea Biopharmaceuticals is a precision medicine company developing immuno-targeted diagnostic and therapeutic products based on its patented Manocept platform, which targets the CD206 receptor on macrophages. The platform enables detection of undiagnosed disease in oncology, autoimmune, and inflammatory conditions, with the goal of improving diagnostic accuracy and guiding treatment decisions. The company's lead product, Lymphoseek (Tc99m-tilmanocept), has completed Phase 3 trials for breast cancer and melanoma and is commercially available in select markets. Additionally, Navidea has explored applications in rheumatoid arthritis, Alzheimer's disease (via [18F]NAV4694), and other indications through completed early-stage trials. The Manocept platform remains a versatile tool for macrophage imaging, with potential for expansion into new indications and therapeutic conjugates.